Gilbert changed his life with Vida
Member Story
Resources
-
The Viewpoint from Vida: what happens after GLP-1s?
Whether or not someone continues GLP-1 therapy is a clinical decision that should be made in partnership with their healthcare provider. But what are the strategic benefits, and what are the risks?
-
7 Reasons Employers and Health Plans Need to Get Ahead of MASH Costs
MASH isn’t a new problem, it’s a newly visible one. As obesity and diabetes continue to drive healthcare costs, metabolic liver disease is emerging as a critical missing piece in many employer strategies.
-
Expanding access to obesity care: Breaking the cost barrier through innovative benefit design
Watch the on-demand webinar that takes a deep dive into how organizations can respond to GLP-1 demand even when the medications aren’t covered on their formulary.